Status: Not yet recruiting
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function
This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Assembly BiosciencesUpdated: Oct 1, 2026Locations: 1
Eligibility criteria
Participant is willing and able to provide written informed consent, is availabl... [+11]
Child-Pugh score >6 at Screening. [+32]